Abbott (ABT) Form 4: Officer Sells 79 Shares at $132.66

Abbott Laboratories reporting person John A. McCoy Jr., Vice President and Controller, is disclosed as selling 79 common shares on 09/01/2025 at a price of $132.66 per share.

Rhea-AI Filing Summary

Abbott Laboratories reporting person John A. McCoy Jr., Vice President and Controller, is disclosed as selling 79 common shares on 09/01/2025 at a price of $132.66 per share. After the reported disposition, Mr. McCoy beneficially owns 20,982 common shares directly. The filing also notes an indirect interest in Abbott shares held in a profit sharing/stock retirement trust, with the balance in that trust stated as of September 1, 2025. The Form 4 is signed by an attorney-in-fact on behalf of Mr. McCoy on 09/03/2025.

Positive

• Transparent disclosure of transaction date, price, and post-transaction ownership in compliance with Section 16
• Indirect holdings in the profit sharing/stock retirement trust are explicitly noted, improving clarity

Negative

• None.

Insights

Financial Analyst

TL;DR: Officer executed a small, single-transaction sale; ownership remained material but largely unchanged.

The Form 4 shows a single non-derivative sale of 79 common shares at $132.66 on 09/01/2025, leaving 20,982 shares beneficially owned. For a company of Abbott's scale, this transaction size is minor and does not indicate a material shift in insider stake or firm capitalization. The disclosure of an indirect interest via the company stock retirement/profit sharing trust is routine for compensation-related holdings and is explicitly acknowledged in the filing. No derivative transactions, option exercises, or additional dispositions are reported.

Corporate Governance Expert

TL;DR: Routine insider sale recorded and properly disclosed; indirect trust holdings are documented.

The report identifies John A. McCoy Jr. as the filing insider and indicates the sale was reported under Form 4 procedures with an attorney-in-fact signature. The filing documents both direct ownership (20,982 shares post-sale) and indirect ownership through a profit sharing/stock retirement trust as of 09/01/2025. The submission appears to comply with Section 16 reporting requirements with clear transaction date, price, and ownership figures. There are no indications of related-party or unusual arrangements disclosed in this document.

Insider Trade Summary

Exercise Price or Tax Liability: 79 shares

Exercise Price or Tax Liability 2 txns

Insider MCCOY JOHN A. JR.

Role VICE PRESIDENT AND CONTROLLER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common shares without par value	79	$132.66	$10K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 20,982 shares (Direct); Common shares without par value — 57 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2025.

FAQ

What transaction did Abbott (ABT) insider John A. McCoy Jr. report on Form 4?

The filing reports a sale of 79 common shares on 09/01/2025 at $132.66 per share.

How many Abbott shares does John A. McCoy Jr. beneficially own after the reported sale?

After the reported disposition, he beneficially owns 20,982 common shares.

Does the Form 4 indicate any indirect ownership for the reporting person?

Yes. The filing discloses an indirect interest through a profit sharing/stock retirement trust, with the trust balance noted as of September 1, 2025.

When was the Form 4 signed and by whom?

The Form 4 was signed 09/03/2025 by John A. McCoy, Jr. via attorney-in-fact Jessica H. Paik.

Were there any derivative transactions reported in this Form 4?

No. The filing contains only a non-derivative sale of common shares and lists no derivative securities transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCOY JOHN A. JR.

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VICE PRESIDENT AND CONTROLLER

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	09/01/2025		F		79	D	$132.66	20,982	D
Common shares without par value								57(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2025.

	/s/ John A. McCoy, Jr. by Jessica H. Paik, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.